« Tykerb Also Fights Breast Cancer that has Spread to Brain | Main | Trial Shows Gabapentin Reduced Alcohol Craving and Consumption »

Dec18
Forest Labs and Mylan's Bystolic Gets FDA Approval for Hypertension

Forest Laboratories Inc. (NYSE:FRX) and Mylan Inc.(NYSE:MYL) have received U.S. Food and Drug Administration approval for their beta blocker Bystolic.

Bystolic, indicated for the treatment of hypertension, is a one daily medication that can be used in conjunction with other high blood pressure drugs or alone. The drug is a beta blocker which is one of the most prescribed classes of drug in the U.S. In several clinical trials Bystolic showed significant decreases in sitting diastolic and systolic blood pressure in a group of patients that included 26 percent black, 54 percent male, 19 percent elderly and 8 percent diabetic.

Hypertension Machine"Bystolic is the newest beta blocker approved for the treatment of hypertension in the U.S. and should prove useful due to its efficacy in a broad range of patients and its favorable side effect profile," said Michael Weber, MD, Professor of Medicine at SUNY Downstate College of Medicine. "These features will be attractive to both physicians and patients."

Howard Solomon, Chairman and Chief Executive of Forest, commented: "We, along with our partner Mylan, are pleased to have received final Food and Drug Administration marketing approval for Bystolic. Bystolic represents an important advance for patients with hypertension and the physicians who treat them and will be an important new product for our Company."

Bystolic was found to be well tolerated with minimal incidence of traditional beta blocker side effects. The drug decreases heart rate and myocardial contractility and suppresses renin activity. Bystolic is already approved and marketed in more than 50 countries worldwide.

The most common side effects of Bystolic were headache, dizziness and fatigue. Patients are advised against abrupt discontinuation of the drug and those with severe bradycardia, cardiogenic shock, decompensated cardiac failure, severe hepatic impairment, peripheral vascular disease and severe renal impairment are cautioned or contraindicated from using the drug.

[Source: PRNewsWire


0 Comments/Trackbacks




submit a trackback

TrackBack URL for this entry:

post a comment

Name, Email Address, and URL are not required fields.





Comment Preview

« Tykerb Also Fights Breast Cancer that has Spread to Brain | Main | Trial Shows Gabapentin Reduced Alcohol Craving and Consumption »

Advertise

Watch the Digital Health Revolution


sponsored ads



subscribe


Prefer Email?
Subscribe below-

Enter your Email:


Powered by FeedBlitz What's this?

Current News

Support This Blog

top blogs

business social media

Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!

BIZZlogos - Add your logo - free link to your site
BIZZphotos - Add photos of your products and people
BIZZprofiles - Submit your profile and build your online visibility
BIZZspotlight - Spotlight your business with free links
BIZZvideos - Videos about businesses, products and business people.
BIZZbites - "Digg" for Business - Submit your articles and posts

know more media network

View Network Map

Network Feed List (OPML)

Know More Media Network
Feed


we support unitus

PRWeb

Influencer



PharmaGazette is a member of the Know More Media network of business related blogs.

Here are some current headlines from some of our business publications:

ProductivityGoal

CallCenterScript

AdHurl

TheBizofKnowledge

LandingTheDeal

CustomersAreAlways

HealthCareVox

BrainBasedBusiness

TheInsurancePolicy

MarketingBlurb